Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know

Company Overview - Taysha Gene Therapies, Inc. (TSHA) is expected to report a year-over-year increase in earnings due to higher revenues for the quarter ended June 2025, with a consensus outlook indicating a quarterly loss of $0.07 per share, representing a 22.2% improvement from the previous year [1][3] - Revenues are anticipated to reach $1.72 million, reflecting a 55% increase compared to the same quarter last year [3] Earnings Estimates and Trends - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial projections [4] - The Most Accurate Estimate for Taysha Gene Therapies is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -14.29%, suggesting a bearish outlook from analysts [12] Earnings Surprise Prediction - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - Taysha Gene Therapies currently holds a Zacks Rank of 2, but the negative Earnings ESP complicates the prediction of an earnings beat [12] Historical Performance - In the last reported quarter, Taysha Gene Therapies was expected to post a loss of $0.08 per share and did so, resulting in no surprise [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - Amphastar Pharmaceuticals (AMPH), another player in the Zacks Medical - Generic Drugs industry, is expected to report earnings per share of $0.71 for the same quarter, indicating a year-over-year decline of 24.5% [18] - Revenues for Amphastar are projected to be $169.84 million, down 6.9% from the previous year, with an Earnings ESP of -11.97% [19][20]